Vitexnegheteroin

Vitexnegheteroin is a chromone derivative (C20H18O6, MW 354) isolated from Vitex negundo leaves, featuring methoxy and hydroxyl substituents on a chromone ring system that confer anti-inflammatory and analgesic activity, likely through inhibition of inflammatory mediator pathways inferred from in vivo animal models. Evidence remains preclinical: methanolic leaf extracts containing this and related iridoid glycoside fractions show radical-scavenging IC50 values of 45–79 mg/mL in DPPH assays, with no human clinical trial data currently available.

Origin & History

Vitexnegheteroin is a chromone-class secondary metabolite isolated from the leaves of Vitex negundo (five-leaved chaste tree), a shrub native to tropical and subtropical Asia, including India, China, and Southeast Asia. The parent plant thrives in riverbanks, scrublands, and disturbed habitats across South and East Asia, and has been cultivated in Ayurvedic medicine for millennia. The compound is obtained from leaf tissue of wild-harvested or micropropagated V. negundo plants, with in-vitro callus cultures using BAP (2.0 mg/L) and 2,4-D (0.2 mg/L) proposed as a scalable biosynthetic source.

Historical & Cultural Context

Vitex negundo, the botanical source of vitexnegheteroin, has been used for over two millennia in Ayurvedic medicine under the name 'nirgundi,' where its leaves, roots, and bark were prescribed for pain relief, fever reduction, inflammation, and diseases attributed to vata and kapha dosha imbalance. Classical Ayurvedic texts including the Charaka Samhita and Sushruta Samhita reference the plant as a potent analgesic and anti-inflammatory agent, used topically as a leaf poultice for joint pain and internally as a decoction for mastodynia and hyperprolactinemia. In traditional Chinese medicine and Southeast Asian folk medicine, the plant was similarly employed for headaches, rheumatic disorders, and microbial infections, often prepared as a fumigant or aromatic bath owing to the pungent, bitter volatile compounds in the leaves. The modern isolation of vitexnegheteroin as a discrete chromone derivative represents a scientific effort to identify and characterize the specific phytochemicals responsible for this broad ethnopharmacological activity.

Health Benefits

- **Antioxidant Activity**: Chromone constituents including vitexnegheteroin contribute to radical-scavenging capacity measured at IC50 45.305 mg/mL (acetone extract) and 79.365 mg/mL (methanol extract) in DPPH assays, with terpenoids such as D-viridiflorol (6.79% of leaf volatile fraction) synergistically neutralizing free radicals.
- **Anti-Inflammatory Effects**: In vivo animal studies demonstrate that chromone fractions from V. negundo leaves exert anti-inflammatory activity, attributed to the carbonyl and aromatic systems of the chromone ring (IR bands 1675–1580 cm⁻¹) that may interfere with pro-inflammatory signaling cascades.
- **Analgesic Properties**: Isolated chromone derivatives, including vitexnegheteroin, have shown analgesic effects in animal models, consistent with traditional Ayurvedic use of V. negundo for pain management; exact receptor targets remain under investigation.
- **Antimicrobial Potential**: Leaf extracts of V. negundo containing vitexnegheteroin and co-occurring benzene derivatives (e.g., 1-methoxy-4-(1-propenyl)-benzene at 4.28%) demonstrate broad-spectrum antimicrobial activity in vitro, though minimum inhibitory concentrations specific to this compound alone have not been isolated.
- **Hormonal Modulation (Prolactin Reduction)**: Phytochemicals from V. negundo, within the fraction containing chromone derivatives, are associated with reduction of serum prolactin in hyperprolactinemia models, suggesting possible dopaminergic or direct pituitary pathway modulation.
- **Antipyretic Activity**: Traditional and preclinical pharmacological data attribute antipyretic properties to V. negundo leaf fractions that include chromone compounds, consistent with the plant's Ayurvedic classification as a treatment for fever and inflammatory conditions.
- **Anthelmintic Effects**: Bioactive fractions of V. negundo leaves, encompassing terpenoids and chromone derivatives, exhibit anthelmintic activity in traditional and early experimental contexts, though controlled mechanistic studies specific to vitexnegheteroin are lacking.

How It Works

Vitexnegheteroin's chromone ring system (confirmed by NMR signals at δ 12.10 for hydroxyl and δ 3.72 for methoxy groups, and IR carbonyl/aromatic bands at 1675–1580 cm⁻¹) is believed to facilitate hydrogen atom transfer or single electron transfer to neutralize reactive oxygen species, consistent with the broad radical-scavenging activity observed in DPPH assays of V. negundo extracts. The methoxy and hydroxyl substituents on the chromone scaffold increase electron density at reactive positions, enhancing antioxidant potency relative to unsubstituted chromone. Anti-inflammatory and analgesic mechanisms are not fully elucidated at the molecular level but are inferred from in vivo animal model outcomes, potentially involving suppression of cyclooxygenase enzymes or inhibition of NF-κB-mediated cytokine release, pathways commonly associated with plant-derived chromone compounds. Prolactin-lowering activity observed in the broader V. negundo extract context may involve modulation of dopaminergic receptor signaling in the pituitary, though direct receptor binding data for vitexnegheteroin specifically are absent from published literature.

Scientific Research

The evidence base for vitexnegheteroin is exclusively preclinical, comprising GC-MS phytochemical profiling of V. negundo leaf and callus extracts, isolation studies confirmed by NMR/IR/UV/MS spectroscopy, and in vitro antioxidant assays alongside in vivo animal pharmacology. No randomized controlled trials, observational human studies, or clinical pharmacokinetic studies have been conducted specifically on vitexnegheteroin as an isolated compound. In vitro DPPH radical-scavenging IC50 values for crude extracts range from 45.305 mg/mL (acetone) to 79.365 mg/mL (methanol), indicating moderate antioxidant activity, but these values reflect the entire extract matrix and cannot be attributed solely to vitexnegheteroin. The scientific literature characterizing this compound is limited to a small number of isolation and preliminary pharmacology studies, and the overall evidence quality is insufficient to support therapeutic claims in humans without further clinical investigation.

Clinical Summary

No human clinical trials have been conducted on vitexnegheteroin as an isolated compound or as a standardized fraction; all available pharmacological data derive from in vitro cell-free assays and in vivo rodent models using crude or semi-purified V. negundo extracts. Anti-inflammatory and analgesic outcomes measured in animal studies show activity consistent with chromone pharmacophore behavior, but effect sizes, therapeutic indices, and human-relevant dosing cannot be extrapolated from these data. The broader V. negundo ethnopharmacological literature documents traditional efficacy for pain, fever, and hyperprolactinemia, providing biological plausibility but not clinical proof of efficacy for vitexnegheteroin specifically. Confidence in clinical benefit is low; rigorous dose-escalation, bioavailability, and efficacy trials in humans are required before therapeutic recommendations can be made.

Nutritional Profile

Vitexnegheteroin is a pure phytochemical compound (C20H18O6, MW 354.35 g/mol) and does not constitute a significant source of macronutrients or micronutrients. The parent leaf matrix of V. negundo contains diverse secondary metabolites including octadecadienoic acid (21.93% of wild leaf volatile fraction), hexadecanoic acid methyl ester, D-viridiflorol (6.79%), 1-methoxy-4-(1-propenyl)-benzene (4.28%), tridecanedialdehyde, drimenol, flavonoids, iridoid glycosides, and phytosteroids. The compound itself possesses two methoxy groups and one hydroxyl group on its chromone scaffold, which govern its polarity and likely moderate lipophilicity (estimated logP ~2–3 for similar chromones), potentially affecting oral bioavailability, though no experimental bioavailability data for vitexnegheteroin are published. Bioavailability factors such as first-pass metabolism, plasma protein binding, and tissue distribution have not been characterized.

Preparation & Dosage

- **Methanolic Leaf Extract (Research Grade)**: Used in experimental studies at concentrations sufficient to yield IC50 of 45–79 mg/mL in DPPH assays; no human-equivalent dose established.
- **Acetone Leaf Extract (Research Grade)**: Demonstrates superior radical-scavenging activity (IC50 45.305 mg/mL) compared to methanol extract in in vitro models; not available as a standardized commercial supplement.
- **Traditional Ayurvedic Leaf Preparation**: Leaves decocted or powdered for oral use in traditional medicine; specific doses varied by practitioner and indication, with no modern standardized equivalent validated by clinical trials.
- **Isolated Chromone Fraction**: Obtained via column chromatography from leaf extracts; characterized as yellow solids (C20H18O6, MW 354); used exclusively in research settings with no established therapeutic dose.
- **In-Vitro Callus-Derived Extract**: Micropropagated callus cultures (BAP 2.0 mg/L, 2,4-D 0.2 mg/L) yield octadecadienoic acid concentrations roughly double those of wild plants and are proposed as a future standardized source, but no commercial product exists.
- **Standardization**: No standardization percentage for vitexnegheteroin content in any commercial product has been established or validated.

Synergy & Pairings

Vitexnegheteroin may act synergistically with co-occurring terpenoids in V. negundo leaf extracts, particularly D-viridiflorol and octadecadienoic acid, which contribute complementary radical-scavenging mechanisms through hydrogen atom donation and lipid peroxidation inhibition, thereby broadening antioxidant coverage across aqueous and lipid phases. Co-administration with flavonoid-rich botanicals such as quercetin or rutin is theoretically synergistic given shared chromone-scaffold chemistry and overlapping anti-inflammatory pathway modulation, though no experimental evidence for this combination with vitexnegheteroin specifically exists. In the context of Ayurvedic formulations, V. negundo is traditionally combined with other adaptogenic and anti-inflammatory herbs such as ashwagandha (Withania somnifera), which may provide complementary stress-axis and NF-κB modulating effects, though combined pharmacokinetic and pharmacodynamic studies are lacking.

Safety & Interactions

Safety data specific to vitexnegheteroin as an isolated compound are absent from the published literature, and no toxicology studies, maximum tolerated dose studies, or chronic exposure data have been reported. The parent plant V. negundo is traditionally regarded as generally safe in customary Ayurvedic doses, with leaves described as aromatic, bitter, pungent, and astringent, and no acute toxicity has been noted in phytochemical profiling studies. Potential drug interactions are not documented for vitexnegheteroin; however, the broader V. negundo extract's prolactin-lowering and possible dopaminergic activity raises a theoretical concern for interactions with dopamine agonists, antipsychotics, and hormonal therapies. Pregnancy and lactation safety are unestablished; given the plant's traditional use to reduce prolactin and its uterine activity described in ethnobotanical sources, use during pregnancy or breastfeeding is not recommended without medical supervision.